Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.57 |
| ▸ | F10 | P00742 | 1/20 | 0.55 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016346 | 0.89 | SRD5A2 (0.56) | SRD5A2F10LTB4RLTB4R2MEN1 | |
| SCHEMBL18733284 | 0.85 | LTB4R (0.63) | SRD5A2F10LTB4RLTB4R2MEN1 | |
| SCHEMBL8687408 | 0.84 | SRD5A2 (0.76) | SRD5A2F10LTB4RLTB4R2MEN1 | |
| SCHEMBL15908729 | 0.83 | SRD5A2 (0.61) | SRD5A2F10LTB4RLTB4R2MEN1 | |
| SCHEMBL2970721 | 0.83 | SRD5A2 (0.49) | SRD5A2F10LTB4RLTB4R2MEN1 | |
| SCHEMBL2430844 | 0.83 | SRD5A2 (0.55) | SRD5A2F10LTB4RLTB4R2MEN1 | |
| SCHEMBL2015584 | 0.82 | SRD5A2 (0.63) | SRD5A2LTB4RLTB4R2MEN1KMT2A | |
| SCHEMBL18733288 | 0.81 | LTB4R (0.55) | SRD5A2F10LTB4RLTB4R2MEN1 | |
| SCHEMBL3639123 | 0.81 | SRD5A2 (0.61) | SRD5A2F10LTB4RLTB4R2MEN1 | |
| SCHEMBL1553259 | 0.79 | SRD5A2 (0.58) | SRD5A2F10LTB4RLTB4R2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786109-B2 | Tricyclic amide derivatives as modulators of H3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1960401-B1 | TRICYCLIC AMIDE DERIVATIVES USEFUL FOR TREATING OBESITY | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7579351-B2 | Tricyclic amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090156583-A1 | Tricyclic Amide Derivatives | NETTEKOVEN MATTHIAS | 2009-06-18 | — | — | US | disclosed |
| EP-1960401-A1 | TRICYCLIC AMIDE DERIVATIVES USEFUL FOR TREATING OBESITY | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070135416-A1 | Tricyclic amide derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007065820-A1 | TRICYCLIC AMIDE DERIVATIVES USEFUL FOR TREATING OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156583-A1 | Tricyclic Amide Derivatives | HRH4, HRH3, HCAR1 | SRD5A2 1339/4885F10 2855/4885LTB4R 335/4885 |
| US-20070135416-A1 | Tricyclic amide derivatives | HRH4, HRH3, HCAR1 | SRD5A2 1339/4885F10 2855/4885LTB4R 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.